Olazagoitia Garmendia, AneSebastian de la Cruz, MaialenBergara Muguruza, LeireRojas Márquez, HenarHuerta Madrigal, AlainSantin Gomez, IzortzeCastellanos Rubio, Ainara2024-11-272024-11-27production.46804https://dx.doi.org/10.26876/ikergazte.v.04.13https://gordailua.ueu.eus/handle/123456789/2699Zitokinek eragindako hantura kronikoak gaixotasun konplexu desberdinak garatzeko arriskua areagotzen du, hala nola, hesteetako hanturazko gaixotasuna. Azken urtetako ikerketek hantura geneetan dauden aldaerek m6A metilazioan duten parte-hartzea nabarmendu dute. Gainera, RNA luze ez kodetzaileek hanturazko gaixotasunen patogenian parte hartzen dute eta RNA metilazioak haien funtzioan eragin dezake. Hemen hesteetako hanturazko gaixotasunaren garapenean parte hartzen duen LOC339803 RNA luze ez kodetzailearen azterketa funtzionala deskribatzen dugu. Orokorrean, gure emaitzek LOC339803 hesteetako hanturaren bitartekari garrantzitsu gisa aurkezten dute eta RNA luze ez kodetzaile hau hesteetako hanturazko gaixotasuna tratatzeko balizko itu terapeutiko berri gisa aurkezten dugu.Cytokine mediated sustained inflammation increases the risk to develop different complex chronic inflammatory diseases, such as inflammatory bowel disease. Recent studies highlighted the involvement of inflammation associated gene variants in m6A methylation. Moreover, long noncoding RNAs participate in the pathogenesis of inflammatory disorders and their function can be influenced by differential methylation. Here we describe the functional implication of LOC339803 long noncoding RNA in the development of inflammatory bowel disease. Overall, our results support LOC339803 as an important mediator of intestinal inflammation and we present this long noncoding RNA as a potential novel therapeutic target for the treatment of inflammatory bowel disease.lncRNASNPm6AhanturaHHGRNA terapiaklncRNASNPm6AinflammationIBDRNA therapiesMedikuntzaintroduction